Hookipa Pharma (HOOK) Competitors $1.84 -0.02 (-1.08%) As of 01/6/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HOOK vs. RGLS, NVCT, ORMP, APLT, VERU, PYXS, IMUX, KPTI, ALXO, and RANIShould you be buying Hookipa Pharma stock or one of its competitors? The main competitors of Hookipa Pharma include Regulus Therapeutics (RGLS), Nuvectis Pharma (NVCT), Oramed Pharmaceuticals (ORMP), Applied Therapeutics (APLT), Veru (VERU), Pyxis Oncology (PYXS), Immunic (IMUX), Karyopharm Therapeutics (KPTI), ALX Oncology (ALXO), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical preparations" industry. Hookipa Pharma vs. Regulus Therapeutics Nuvectis Pharma Oramed Pharmaceuticals Applied Therapeutics Veru Pyxis Oncology Immunic Karyopharm Therapeutics ALX Oncology Rani Therapeutics Hookipa Pharma (NASDAQ:HOOK) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends, community ranking and earnings. Which has stronger valuation and earnings, HOOK or RGLS? Regulus Therapeutics has lower revenue, but higher earnings than Hookipa Pharma. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHookipa Pharma$50.00M0.44-$81.58M-$3.72-0.49Regulus TherapeuticsN/AN/A-$30.04M-$1.07-1.45 Do analysts rate HOOK or RGLS? Hookipa Pharma presently has a consensus target price of $23.00, indicating a potential upside of 1,150.00%. Regulus Therapeutics has a consensus target price of $10.80, indicating a potential upside of 596.77%. Given Hookipa Pharma's higher probable upside, analysts plainly believe Hookipa Pharma is more favorable than Regulus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hookipa Pharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Regulus Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more volatility and risk, HOOK or RGLS? Hookipa Pharma has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Is HOOK or RGLS more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Hookipa Pharma's return on equity of -33.31% beat Regulus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Hookipa Pharma-86.74% -33.31% -21.65% Regulus Therapeutics N/A -53.07%-48.58% Do insiders & institutionals believe in HOOK or RGLS? 63.9% of Hookipa Pharma shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 3.3% of Hookipa Pharma shares are owned by company insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer HOOK or RGLS? In the previous week, Hookipa Pharma had 5 more articles in the media than Regulus Therapeutics. MarketBeat recorded 5 mentions for Hookipa Pharma and 0 mentions for Regulus Therapeutics. Hookipa Pharma's average media sentiment score of 0.21 beat Regulus Therapeutics' score of 0.00 indicating that Hookipa Pharma is being referred to more favorably in the media. Company Overall Sentiment Hookipa Pharma Neutral Regulus Therapeutics Neutral Does the MarketBeat Community favor HOOK or RGLS? Regulus Therapeutics received 399 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 70.00% of users gave Hookipa Pharma an outperform vote while only 63.80% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformHookipa PharmaOutperform Votes9170.00% Underperform Votes3930.00% Regulus TherapeuticsOutperform Votes49063.80% Underperform Votes27836.20% SummaryRegulus Therapeutics beats Hookipa Pharma on 9 of the 17 factors compared between the two stocks. Ad Investors AlleyCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…Click here to discover the new #1 way to invest in Tesla Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOOK vs. The Competition Export to ExcelMetricHookipa PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.18M$6.58B$5.21B$9.16BDividend YieldN/A2.91%5.30%4.19%P/E Ratio-0.4910.5287.6417.30Price / Sales0.44196.691,103.33129.05Price / CashN/A57.1143.2637.86Price / Book0.205.195.225.22Net Income-$81.58M$152.86M$121.39M$226.72M7 Day Performance-8.91%5.87%5.13%3.96%1 Month Performance-26.69%0.64%21.52%5.41%1 Year Performance-75.31%6.29%32.16%22.16% Hookipa Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOOKHookipa Pharma3.1596 of 5 stars$1.84-1.1%$23.00+1,150.0%-75.3%$22.18M$50.00M-0.4956News CoverageGap UpRGLSRegulus Therapeutics1.4375 of 5 stars$1.50-2.9%$10.80+622.4%+17.4%$97.92MN/A-1.4030NVCTNuvectis Pharma2.3982 of 5 stars$5.05-3.3%$21.00+315.8%-28.5%$97.57MN/A-4.358Positive NewsORMPOramed Pharmaceuticals1.7828 of 5 stars$2.39+0.8%N/A-0.8%$96.35M$1.34M21.7310Analyst DowngradeAPLTApplied Therapeutics4.5375 of 5 stars$0.82-4.5%$6.10+648.2%-61.1%$94.87M$-212,000.00-0.5130VERUVeru2.0868 of 5 stars$0.65-4.2%$4.00+518.0%+28.6%$94.74M$16.89M-1.35189Gap UpPYXSPyxis Oncology1.3796 of 5 stars$1.56-1.9%$9.43+504.4%-16.6%$92.77M$16.15M-1.5160IMUXImmunic1.9303 of 5 stars$1.03-0.5%$11.80+1,051.2%-21.6%$92.33MN/A-0.8370KPTIKaryopharm Therapeutics3.7942 of 5 stars$0.73+4.0%$5.00+585.6%+0.9%$92.03M$148.44M-0.64380ALXOALX Oncology3.6049 of 5 stars$1.66+2.5%$8.50+412.0%-85.8%$87.55MN/A-0.5640RANIRani Therapeutics2.4402 of 5 stars$1.53+7.4%$11.71+668.1%-50.0%$87.37M$2.72M-1.44110Gap Down Related Companies and Tools Related Companies Regulus Therapeutics Competitors Nuvectis Pharma Competitors Oramed Pharmaceuticals Competitors Applied Therapeutics Competitors Veru Competitors Pyxis Oncology Competitors Immunic Competitors Karyopharm Therapeutics Competitors ALX Oncology Competitors Rani Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOOK) was last updated on 1/7/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hookipa Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HOOK Stock Alerts